348 related articles for article (PubMed ID: 22316106)
1. African American patients with gout: efficacy and safety of febuxostat vs allopurinol.
Wells AF; MacDonald PA; Chefo S; Jackson RL
BMC Musculoskelet Disord; 2012 Feb; 13():15. PubMed ID: 22316106
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.
Jackson RL; Hunt B; MacDonald PA
BMC Geriatr; 2012 Mar; 12():11. PubMed ID: 22436129
[TBL] [Abstract][Full Text] [Related]
3. Diabetes and gout: efficacy and safety of febuxostat and allopurinol.
Becker MA; MacDonald PA; Hunt BJ; Jackson RL
Diabetes Obes Metab; 2013 Nov; 15(11):1049-55. PubMed ID: 23683134
[TBL] [Abstract][Full Text] [Related]
4. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.
Becker MA; Schumacher HR; Espinoza LR; Wells AF; MacDonald P; Lloyd E; Lademacher C
Arthritis Res Ther; 2010; 12(2):R63. PubMed ID: 20370912
[TBL] [Abstract][Full Text] [Related]
5. Can racial disparities in optimal gout treatment be reduced? Evidence from a randomized trial.
Singh JA
BMC Med; 2012 Feb; 10():15. PubMed ID: 22316088
[TBL] [Abstract][Full Text] [Related]
6. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL
Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
[TBL] [Abstract][Full Text] [Related]
8. Allopurinol for chronic gout.
Seth R; Kydd AS; Buchbinder R; Bombardier C; Edwards CJ
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD006077. PubMed ID: 25314636
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study.
Gunawardhana L; Becker MA; Whelton A; Hunt B; Castillo M; Saag K
Arthritis Res Ther; 2018 May; 20(1):99. PubMed ID: 29848361
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of febuxostat versus allopurinol and the predictors of achieving target serum urate in a cohort of Thai people with gout.
Lertnawapan R; Jatuworapruk K
Clin Rheumatol; 2021 Jan; 40(1):255-262. PubMed ID: 32607660
[TBL] [Abstract][Full Text] [Related]
11. As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.
Tausche AK; Christoph M; Forkmann M; Richter U; Kopprasch S; Bielitz C; Aringer M; Wunderlich C
Rheumatol Int; 2014 Jan; 34(1):101-9. PubMed ID: 24026528
[TBL] [Abstract][Full Text] [Related]
12. Urate-lowering therapy for gout: focus on febuxostat.
Love BL; Barrons R; Veverka A; Snider KM
Pharmacotherapy; 2010 Jun; 30(6):594-608. PubMed ID: 20500048
[TBL] [Abstract][Full Text] [Related]
13. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
[TBL] [Abstract][Full Text] [Related]
14. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
[TBL] [Abstract][Full Text] [Related]
15. Preservation of renal function during gout treatment with febuxostat: a quantitative study.
Whelton A; MacDonald PA; Chefo S; Gunawardhana L
Postgrad Med; 2013 Jan; 125(1):106-14. PubMed ID: 23391676
[TBL] [Abstract][Full Text] [Related]
16. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis.
Ye P; Yang S; Zhang W; Lv Q; Cheng Q; Mei M; Luo T; Liu L; Chen S; Li Q
Clin Ther; 2013 Feb; 35(2):180-9. PubMed ID: 23332451
[TBL] [Abstract][Full Text] [Related]
18. Effects of intensive urate lowering therapy with febuxostat in comparison with allopurinol on pulse wave velocity in patients with gout and increased cardiovascular risk: the FORWARD study.
Desideri G; Rajzer M; Gerritsen M; Nurmohamed MT; Giannattasio C; Tausche AK; Borghi C
Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):236-242. PubMed ID: 33410912
[TBL] [Abstract][Full Text] [Related]
19. A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia.
Xu S; Liu X; Ming J; Chen S; Wang Y; Liu X; Liu H; Peng Y; Wang J; Lin J; Ji H; Liu B; Lu Y; Liu P; Zhang Y; Ji Q
Int J Rheum Dis; 2015 Jul; 18(6):669-78. PubMed ID: 26013187
[TBL] [Abstract][Full Text] [Related]
20. Design and Rationale for the Veterans Affairs "Cooperative Study Program 594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat" Trial.
Timilsina S; Brittan K; O'Dell JR; Brophy M; Davis-Karim A; Henrie AM; Neogi T; Newcomb J; Palevsky PM; Pillinger MH; Pittman D; Taylor TH; Wu H; Mikuls TR
Contemp Clin Trials; 2018 May; 68():102-108. PubMed ID: 29597007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
